Record number:
246
Adverse Occurrence type:
MPHO Type:
Estimated frequency:
- Most recent risk assessment for breast cancer (Council of Europe, 2025):
Breast cancer diagnosed during donor procurement: Newly diagnosed invasive breast cancer is an unacceptable risk for organ donation.
Breast cancer in the donor history: Organs from donors with invasive breast cancer might be accepted in selected cases after full treatment, complete remission and stringent follow-up for > 5 years, depending on the initial stage and E/P and HER2/neu receptor expression, always bearing in mind the risk of transmission due to possible late metastases.
Breast cancer stage 1A (T1, N0; AJCC, 8th edition) with curative surgery and cancer-free period > 5 years seems to be associated with low to intermediate risk for transmission. All other invasive breast cancer stages are considered high risk for transmission, independent of the presumed recurrence-free survival and treatment. High nuclear grade ductal carcinoma in situ (DCIS) is considered low to intermediate risk for transmission.
Time to detection:
6 months
Alerting signals, symptoms, evidence of occurrence:
Osteolytic bone and central nervous system metastases due to ductal breast adenocarcinoma.
Demonstration of imputability or root cause:
Not specified, except for wife to husband donation. Imputed to be donor origin by type of tumour and resolution with graft rejection
Imputability grade:
3 Definite/Certain/Proven
Groups audience:
Suggest new keywords:
Registry series
Living donor
kidney transplant
ductal adenocarcinoma
Suggest references:
AAA
Expert comments for publication:
According to report, immunosuppression stopped, chemotherapy given. Graft lost and tumor resolved; attributed to tumor rejection but difficult to prove in the setting of chemotherapy. This is one case in this report from the UNOS database